RA0792

antibody from Oursmab

Targeting: TNFSF15 MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0792

Provider

Oursmab

Product name

Duvakitug (Biosimilar Reference Antibody) (TNFSF15)

Antibody type

Monoclonal

Description

Duvakitug (TEV-48574) is an investigational humanized monoclonal antibody being developed by Teva and Sanofi for the treatment of moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC), the two major forms of Inflammatory Bowel Disease (IBD). It functions as a targeted biologic that inhibits a key inflammatory driver, the TL1A protein (also known as TNF-like ligand 1A or TNFSF15). Duvakitug has demonstrated strong efficacy and safety in Phase 2b clinical trials, positioning it as a promising next-generation therapy with the potential to transform IBD care. It is currently advancing into Phase 3 development.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Duvakitug (Biosimilar Reference Antibody) (TNFSF15)-RA0792-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.